Skip to main content

Table 1 Comparison of levels (mean ± SD) of TTR and RBP in serum and asciticfluid in relation to FIGO-stages and levels of CRP in ovarian cancer patients

From: Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients

  serum (μg/mL) ascitic fluid (μg/mL) percentage of serum in ascitic fluid
  TTR RBP TTR RBP TTR RBP
Healthy control n = 20 363.3 ± 105.5 55.8 ± 9.3 - - - -
All Stages ovarian cancer 148.5 ± 96.7 22.5 ± 14.8 1.022 ± 0.239 4.632 ± 1.572 1.0 ± 0.6 26.2 ± 14.9
Stage I/II ovarian cancer 162.5 ± 69.4 34.2 ± 22.3 0.966 ± 0.375 3.580 ± 0.849 0.8 ± 0.6 14.5 ± 9.8
Stage III ovarian cancer 155.6 ± 107.6 19.5 ± 7.5 1.074 ± 0.185 4.800 ± 1.711 1.0 ± 0.6 27.2 ± 11.8
Stage IV ovarian cancer 129.0 ± 96.0 17.4 ± 7.3 0.965 ± 0.241 4.627 ± 1.672 1.2 ± 0.7 32.1 ± 23.3
Ovarian cancer CRP > 40 mg/l 116.0 ± 94.3 14.2 ± 4.3 1.047 ± 0.213 4.736 ± 1.886 1.4 ± 0.7 35.4 ± 17.2
Ovarian cancer CRP < 40 mg/l 166.3 ± 92.1 24.1 ± 12.5 1.005 ± 0.260 4.503 ± 1.415 0.8 ± 0.5 22.3 ± 11.1
  1. All values for ascitic fluid (if available) are significantly different (p < 0.01) from serum value.